Literature DB >> 23628098

[Pronostic value of ureteral location of upper tract urinary carcinoma].

C Le Goux1, G Pignot, D Amsellem-Ouazana, A Vieillefond, M Peyromaure, T Flam, B Debré, M Zerbib.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the prognostic significance of the ureteral location of the upper tract urinary carcinoma (UTUC). PATIENTS AND METHODS: Between January 1998 and December 2007, 161 patients with UTUC were operated in our center. Tumors were located on renal pelvis in 51% of cases, on the ureter in 34% of cases and in both locations in 15% of cases. Nephroureterectomy was performed in 79.5% of cases (128/161) whereas a conservative treatment was performed in 20.5% of cases (33/161).
RESULTS: In our series, 29.8% of patients had primary bladder cancer and 14.3% had synchronous bladder tumor. At a median follow-up of 42.5 months, 38.6% of patients developed bladder recurrence and 4.8% developed controlateral upper tract tumor. In multivariate analysis, ureteral location and existence of synchronous bladder tumor were independent prognostic factors of bladder recurrence (P=0.009 and P=0.025, respectively). Multivariate analysis retained T-stage and ureteral location as independent prognostic factors in both overall and disease-free survival (P=0.002 and P=0.0008 respectively for ureteral location).
CONCLUSION: Ureteral location was an independent prognostic factor of bladder recurrence and was associated with a poorer prognosis.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23628098     DOI: 10.1016/j.purol.2013.01.025

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  1 in total

1.  Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.

Authors:  Marie Simon; Pierre-Olivier Bosset; Mathieu Rouanne; Simone Benhamou; Camelia Radulescu; Vincent Molinié; Yann Neuzillet; Xavier Paoletti; Thierry Lebret
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.